XML 246 R14.htm IDEA: XBRL DOCUMENT v3.22.4
Segment Information
 12 Months Ended
Dec. 31, 2022
Segment Reporting, Measurement Disclosures [Abstract]  
Segment Information SEGMENT INFORMATION
In the fourth quarter of 2022, the Company realigned its reportable segments to reflect changes in the Company’s internal organization resulting from the rate of growth within certain of the Company’s businesses in the former Life Sciences segment. There were no changes to the Company’s Diagnostics or Environmental & Applied Solutions segments.
The Company now operates and reports its results in four separate business segments consisting of the Biotechnology, Life Sciences, Diagnostics and Environmental & Applied Solutions segments. When determining the reportable segments, the Company aggregated operating segments based on their similar economic and operating characteristics. Operating profit represents total revenues less operating expenses, excluding nonoperating income and expense, loss on early extinguishment of borrowings, interest and income taxes. Operating profit amounts in the Other segment consist of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance. The identifiable assets by segment are those used in each segment’s operations. Intersegment amounts are not significant and are eliminated to arrive at consolidated totals. Prior period segment amounts have been restated to conform to the revised segment presentation.
Detailed segment data for the years ended December 31 is as follows ($ in millions):
202220212020
Sales:
Biotechnology$8,758 $8,570 $5,276 
Life Sciences7,036 6,388 5,300 
Diagnostics10,849 9,844 7,403 
Environmental & Applied Solutions4,828 4,651 4,305 
Total$31,471 $29,453 $22,284 
Operating profit:
Biotechnology$3,008 $3,074 $1,082 
Life Sciences1,414 1,293 972 
Diagnostics3,436 2,313 1,538 
Environmental & Applied Solutions1,135 1,054 979 
Other(305)(269)(340)
Total$8,688 $7,465 $4,231 
Depreciation and amortization of intangible assets:
Biotechnology$1,002 $1,059 $761 
Life Sciences531 382 292 
Diagnostics590 614 602 
Environmental & Applied Solutions90 106 110 
Other9 7 10 
Total$2,222 $2,168 $1,775 
The following table presents additional detailed segment data for the years ended December 31 ($ in millions):
202220212020
Identifiable assets:
Biotechnology$37,536 $38,118 $39,086 
Life Sciences17,572 19,768 9,833 
Diagnostics14,722 15,054 15,042 
Environmental & Applied Solutions4,797 4,882 5,083 
Other9,723 5,362 7,117 
Total$84,350 $83,184 $76,161 
Capital expenditures, gross:
Biotechnology$405 $385 $169 
Life Sciences325 210 137 
Diagnostics382 644 447 
Environmental & Applied Solutions34 54 36 
Other6 1 2 
Total$1,152 $1,294 $791 
Operations in Geographical Areas:
Year Ended December 31
($ in millions)202220212020
Sales:
United States$13,365 $11,283 $8,616 
China4,002 3,975 2,688 
Germany1,461 1,482 1,238 
All other (each country individually less than 5% of total sales)
12,643 12,713 9,742 
Total$31,471 $29,453 $22,284 
Property, plant and equipment, net:
United States$2,007 $1,799 $1,317 
Sweden429 513 553 
United Kingdom254 260 214 
Germany225 223 207 
All other (each country individually less than 5% of total property, plant and equipment, net)
1,041 995 971 
Total$3,956 $3,790 $3,262 
Sales by Major Product Group:
Year Ended December 31
($ in millions)202220212020
Analytical and physical instrumentation$2,846 $2,620 $2,443 
Research and medical products26,642 24,802 17,979 
Product identification1,983 2,031 1,862 
Total$31,471 $29,453 $22,284